Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joris Kleintjens

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Pharmacoeconomics|January 12, 2015
Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapyEssè Ifèbi Hervé Akpo, Karin Cerri, Joris Kleintjens
Clinical Therapeutics|November 11, 2011
The economic impact and cost-effectiveness of urinary neutrophil gelatinase-associated lipocalin after cardiac surgeryAndrew D Shaw, Donald B Chalfin, Joris Kleintjens
Drugs in R&D|September 30, 2015
Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced PatientsEssè Ifèbi Hervé Akpo, Urbano Sbarigia, George Wan, et al.
Journal of Medical Economics|September 13, 2025
Budget impact analysis of skytrofa for the treatment of pediatric growth hormone deficiency in a US health planEmily Boller, Subhara Raveendran, Alden Smith, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 25, 2025
Implementing the Generalized Risk-Adjusted Cost-Effectiveness Model for Sickle Cell Disease: A Case StudyMarlon Graf, Joris Kleintjens, Md Tahsin Hasan, et al.
Plos One|June 10, 2021
A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in FranceKaspar Nieland, Antoine Labbé, Cedric Schweitzer, et al.
Applied Health Economics and Health Policy|May 8, 2013
Implications of a data-driven approach to treatment with growth hormone in children with growth hormone deficiency and Turner syndromeStefan Kaspers, Michael B Ranke, Donald Han, et al.
Pharmacoeconomics|September 14, 2013
Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare settingJoris Kleintjens, Xiao Li, Steven Simoens, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Pharmacoeconomics|January 12, 2015
Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapyEssè Ifèbi Hervé Akpo, Karin Cerri, Joris Kleintjens
Clinical Therapeutics|November 11, 2011
The economic impact and cost-effectiveness of urinary neutrophil gelatinase-associated lipocalin after cardiac surgeryAndrew D Shaw, Donald B Chalfin, Joris Kleintjens
Drugs in R&D|September 30, 2015
Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced PatientsEssè Ifèbi Hervé Akpo, Urbano Sbarigia, George Wan, et al.
Journal of Medical Economics|September 13, 2025
Budget impact analysis of skytrofa for the treatment of pediatric growth hormone deficiency in a US health planEmily Boller, Subhara Raveendran, Alden Smith, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 25, 2025
Implementing the Generalized Risk-Adjusted Cost-Effectiveness Model for Sickle Cell Disease: A Case StudyMarlon Graf, Joris Kleintjens, Md Tahsin Hasan, et al.
Plos One|June 10, 2021
A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in FranceKaspar Nieland, Antoine Labbé, Cedric Schweitzer, et al.
Applied Health Economics and Health Policy|May 8, 2013
Implications of a data-driven approach to treatment with growth hormone in children with growth hormone deficiency and Turner syndromeStefan Kaspers, Michael B Ranke, Donald Han, et al.
Pharmacoeconomics|September 14, 2013
Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare settingJoris Kleintjens, Xiao Li, Steven Simoens, et al.
Pageof 1